BioSpace News Archive

Imlifidase benefits highlighted in recent ATC presentations. Expansion outside transplantation with initiation of study in Guillain-Barré Syndrome (GBS) continues.

CARLSMED, Inc., a San Diego-based medical technology company, announced that it has completed a merger with Seattle-based spine imaging system company Precisive Surgical to offer the industry’s first personalized surgical workflow platform.

Senseonics Holdings, Inc. announced the pricing of a registered underwritten public offering of 22,727,273 shares of its common stock at a price to the public of $1.10 per share.

BioArctic AB announces that new data related to BAN2401 were presented on July 17.

Inflection Biosciences, a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences, a company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, announced a global license agreement for Inflection’s first-in-class PIM/PI3K/mTOR inhibitors.

Senseonics Holdings, Inc. announced the pricing of an $82.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Kronos is Focused on the Development of Therapies for Targets Traditionally Viewed as ‘Undruggable’

Kronos Bio, Inc. (Kronos), a Two River portfolio company, announced it has closed a $105 million Series A Preferred Stock financing.

Aurinia Pharmaceuticals Inc. announced the appointments of Mr. Max Donley as Executive Vice President of Internal Operations and Strategy and Dr. Glenn Schulman as Senior Vice President of Corporate Communications and Investor Relations.

One of the nation’s largest hospital networks adopts vascular robotic technology in multiple hospital locations to treat patients in need of cardiovascular care